

## Regorafenib PK Fact Sheet


Reviewed August 2021

Page 1 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

## Details

Generic Name	Regorafenib
Trade Name	Stivarga®
Class	Oncolytics (Protein kinase inhibitors)
Molecular Weight	500.83
Structure	



## Summary of Key Pharmacokinetic Parameters

<i>Linearity/non-linearity</i>	Exposure increases dose proportionally up to 60 mg and less than proportionally doses greater than 60 mg.
<i>Steady state</i>	Time to steady state not reported.
<i>Plasma half-life</i>	Regorafenib and M-2: 20-30 h M-5: ~60 h
<i>C<sub>max</sub></i>	3.9 µg/mL after oral administration of 160 mg, at steady state.
<i>C<sub>24</sub></i>	Not reported
<i>AUC</i>	58.3 µg·h/mL after oral administration of 160 mg, at steady state.
<i>Bioavailability</i>	The mean relative bioavailability of 60 or 100 mg tablets compared to an oral solution is 69% and 83%, respectively.
<i>Absorption</i>	The concentrations of regorafenib and its major pharmacologically active metabolites (M-2 and M-5) are highest when given after a low-fat breakfast, compared to either a high-fat breakfast or fasting condition.
<i>Protein Binding</i>	99.5%.
<i>Volume of Distribution</i>	Not reported.
<i>CSF:Plasma ratio</i>	Not reported.
<i>Semen:Plasma ratio</i>	Not reported.
<i>Renal Clearance</i>	<10% under steady state conditions.
<i>Renal Impairment</i>	No dose adjustment is recommended for patients with renal impairment.
<i>Hepatic Impairment</i>	No dose adjustment is recommended in patients with mild or moderate impairment. Closely monitor patients with hepatic impairment for adverse reactions  Regorafenib is not recommended in patients with severe hepatic impairment as this population has not been studied.

# Regorafenib PK Fact Sheet

Reviewed August 2021

Page 2 of 2

*For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.*

## Metabolism and Distribution

<i>Metabolised by</i>	CYP3A4, UGT1A9.
<i>Inducer of</i>	None known.
<i>Inhibitor of</i>	UGT1A1, UGT1A9, BCRP.
<i>Transported by</i>	BCRP, P-gp.

## References

*Unless otherwise stated (see below), information is from:*

Stivarga® Summary of Product Characteristics, Bayer plc, August 2018.

Stivarga® Prescribing Information, Bayer HealthCare Pharmaceuticals Inc., June 2019.